|Home- - -History-- -Bibliography- -Pregnancy Timeline- --Prescription Drugs in Pregnancy- -- Pregnancy Calculator- --Female Reproductive System- News Alerts -Contact|
Click weeks 0 - 40 and follow fetal growth
Brain Wiring Continues Well Into Our 20s
Vitamin D Deficiency Linked With Severe Asthma
Reprogramming Muscle Stem Cells to Regenerate
BPA Changes In-Vitro Egg, Risking Down Syndrome
'Contaminants' Detected in Narragansett Watershed
New Plastics for Baby Bottles, Shopping Bags, More
Epigenetic Changes Don't Always Last
Vacuum Device Makes Cellular Exploration Easier
11 Genetic Regions Link Schizophrenia/Bipolar Risk
Pediatric Brain Tumors
Crosstalk Between Bone, Fat and Pancreatic Cells
Gene Catastrophe Causes Developmental Delay
Mom's High-Fat Diet 'Programs' Her Baby to Be Fat
Length of Song Linked to Size of Upper Bird Brain
Medulloblastomas constitute the most frequent class of malignant childhood brain tumor. Tumors of this type arise due to the uncontrolled proliferation of immature nerve cells in the developing brain, and there is no targeted treatment available.
A research team based at LMU‘s Center for Neuropathology and Prion Research and led by Privatdozent Dr. Ulrich Schüller has now demonstrated that the regulatory protein FoxM1 is essential for the continued growth of these tumor cells. Moreover, the level of FoxM1 expressed in the cells is significantly, and negatively, correlated with a patient’s survival time. The protein therefore provides a useful prognostic marker, which should allow oncologists to gauge the malignancy of tumors and select the most effective therapeutic strategy for the individual patient.
Furthermore, FoxM1 may provide a novel point of attack for the development of new ways to treat the condition. Schüller and his team were able to reduce FoxM1 levels in tumor cells by exposing them to the antibiotic siomycin A, and showed that the drug also inhibits tumor growth.
“If further work on laboratory cell cultures and in living organisms confirms these results, siomycin could turn out to be an effective drug for the treatment of medulloblastoma,” Schüller says. (Clinical Cancer Research, published OnlineFirst 14.September 2011)
Research conducted over the past 10 years has shown that medulloblastomas arise as a result of aberrant activation of certain molecular signals. Schüller and his team set out to determine whether the transcription factor FoxM1 plays a role in supporting the growth of this type of tumor and, if so, whether it might serve as a drug target for the development of an effective therapy for the disease.
Transcription factors determine the suite of proteins present in a given cell and define which of the genes encoded in the genomic DNA are copied into RNA which then programs a new combination of proteins.
The so-called Forkhead-box (Fox) proteins are factors particularly concerned with the regulation of cell growth, division and differentiation - fully differentiated cells do not proliferate further.
FoxM1 activates genes that promote cell division and simultaneously turns off genes that inhibit proliferation.
Since uncontrolled proliferation is the basic hallmark of cancer cells, understanding and manipulating the function of FoxM1 has become a focus of cancer research. In several different types of cancer, including cancers of the breast, lung and prostate gland, increased amounts of FoxM1 have been found in tumor tissue. Indeed the protein has been shown to be necessary for growth of these tumors. Schüller and his team have now shown that this also true for medulloblastomas.
“One important result was that the amount of FoxM1 present in medulloblastoma cells is correlated with patient survival time,” says Schüller.
Since it is relatively easy to estimate FoxM1 levels using laboratory tests, the molecule could possibly be used as a marker to guide the choice of treatment for each patient. Modern therapeutic options for medulloblastoma involve surgical removal of the tumor, followed by radiation and chemotherapy to eliminate any surviving tumor cells, but this approach has serious side-effects. Furthermore, there are six different subtypes of medulloblastoma, which are markedly differerent in their malignancy and clinical prognosis.
“That is why a good prognostic marker which could predict the aggressiveness of tumors would be so useful,” says Schüller. The clinician could then adapt the therapeutic approach to the patient’s individual needs, and avoid using a sledgehammer to crack a nut.
Since FoxM1 is indispensable for the growth of medulloblastoma cells, it represents a potentially ideal drug target.
With the aid of the antibiotic siomycin A - which specifically inhibits the production of FoxM1 - Schüller was able to inhibit the growth of medulloblastoma cells. His findings confirm and extend results by other groups who have reported that siomycin A also hinders the growth of breast cancer cells.
And most importantly, Schüller‘s experiments showed that although FoxM1 is essential for tumor growth, other factors can apparently substitute for it during normal development. Hence blocking the action of FoxM1 by administering siomycin A should have no bad effects on normal cells.
Thus the antibiotic may make it possible, for the first time, to intervene directly and specifically in the process that gives rise to medulloblastomas, and provide the first therapeutic option that targets a major driver of the growth of such tumors.
The work was carried out by the Max Eder Junior Research Group in Pediatric Neuro-oncology, which is led by Ulrich Schüller and is supported by grants from the Deutsche Krebshilfe. (göd/PH)
Publication: Expression of FoxM1 is required for the proliferation of medulloblastoma cells and indicates worse survival of patients.